证券代码：688222 证券简称：成都先导 公告编号：2025-055 成都先导药物开发股份有限公司 股东拉萨经济技术开发区华博医疗器械有限公司 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 华博器械拟通过集中竞价交易的方式减持其所持有的公司股份不超过 3,000,000 股，拟减持股份占公司总股本的比例约为 0.75%，自减持计划发布之 日起 15 个交易日之后的 3 个月内（2025 年 8 月 26 日至 2025 年 11 月 25 日）实 施，且任意连续 90 个自然日内减持的股份总数不超过公司股份总数的 1%。 | 股东名称 | 拉萨经济技术开发区华博医疗器械有限公司 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 √否 | | □是 | | | 直接持股 □否 | 5%以上股东 | √是 | 一、减持主体减持前基本情况 1 本次减持计划实施前股东持股的基本情况 本次减持计划实施前，成都先导药物开发股 ...

Group 1 - Chengdu XianDao Pharmaceutical Development Co., Ltd. experienced a stock price increase of 5.12%, reaching 22.58 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 1.14%, resulting in a total market capitalization of 9.047 billion CNY [1] - The company, established on February 22, 2012, and listed on April 16, 2020, specializes in early-stage drug discovery services using its core DEL technology, with 99.97% of its revenue coming from new drug development services [1] - The revenue breakdown includes customized services at 59.92%, full-time equivalent services at 27.20%, and other services at 12.84%, with a negligible 0.03% from other sources [1] Group 2 - Huatai-PB Fund has a significant holding in Chengdu XianDao, with the Zhongzheng 2000 fund (563300) holding 453,900 shares, representing 0.52% of the fund's net value, making it the eighth largest holding [2] - The Zhongzheng 2000 fund, established on September 6, 2023, has a current scale of 2.168 billion CNY and has achieved a year-to-date return of 23.2%, ranking 1657 out of 4208 in its category [2] - The fund's one-year return stands at 17.97%, ranking 1859 out of 3981, while its cumulative return since inception is 25.13% [2] Group 3 - The fund managers of Zhongzheng 2000 are Liu Jun and Li Mu Yang, with Liu Jun having a tenure of 16 years and 178 days, managing assets totaling 542.504 billion CNY, achieving a best return of 143.46% and a worst return of -45.64% during his tenure [3] - Li Mu Yang has a tenure of 4 years and 324 days, managing assets of 29.768 billion CNY, with a best return of 121.13% and a worst return of -43.11% during his tenure [3]

Core Viewpoint - Chengdu XianDao has signed a new agreement with the Gates Foundation to develop new drugs for tuberculosis and malaria, as well as non-hormonal contraceptives, utilizing its DNA-encoded compound library (DEL) technology platform [1] Group 1: Agreement Details - The agreement involves screening for new lead compounds targeting 15 drug targets identified by the Gates Foundation and its academic and research partners [1] - The drug discovery work will receive funding support from the Gates Foundation [1] Group 2: Previous Achievements - Chengdu XianDao previously discovered novel lead compounds for malaria and tuberculosis in a project funded by the Gates Foundation, which serves as the foundation for this new initiative [1] Group 3: Company Profile - Chengdu XianDao aims to become a leading innovative biopharmaceutical company globally and is a leader in the development of DEL technology and its application in small molecule drug discovery [1] - The DEL technology platform contains over 1.2 trillion DNA-encoded compounds, and the company's DEL products and efficient screening capabilities have supported numerous drug discovery projects worldwide [1]

Core Viewpoint - Chengdu Xian Dao has signed a new collaboration agreement with the Gates Foundation to utilize its DNA-encoded library (DEL) technology platform for drug discovery targeting unmet medical needs such as tuberculosis and malaria, as well as novel non-hormonal contraceptives [1] Group 1 - Chengdu Xian Dao will screen new lead compounds for 15 drug targets identified in collaboration with the Gates Foundation and its academic and research partners [1] - The drug discovery efforts will receive funding support from the Gates Foundation [1]

Group 1 - The core point of the announcement is the resolution of the second extraordinary general meeting of shareholders held by Chengdu XianDao Pharmaceutical Development Co., Ltd. on November 14, 2025, which included the approval of a proposal to apply for the registration and issuance of non-financial corporate debt financing instruments in the interbank bond market [1][2][3]. - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing a combination of on-site and online voting methods [2][3]. - All nine directors attended the meeting, along with the board secretary and the financial officer, ensuring a quorum for decision-making [4][5]. Group 2 - The proposal regarding the issuance of non-financial corporate debt financing tools was passed with more than half of the valid voting rights held by attending shareholders [3]. - The legal proceedings of the meeting were witnessed by Beijing Junhe (Chengdu) Law Firm, confirming that the meeting's procedures and resolutions were lawful and valid [4][5].

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688222 证券简称：成都先导 公告编号：2025-054 成都先导药物开发股份有限公司 2025年第二次临时股东会决议公告 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 14 日 （二） 股东会召开的地点：成都市双流区慧谷东一路 8 号天府国际生物城 C2 栋成都先导药物开发股份有限公司二楼大会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 133 | | --- | --- | | 普通股股东人数 | 133 | | 2、出席会议的股东所持有的表决权数量 | 173,059,389 | | 普通股股东所持有表决权数量 | 173,059,389 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 43.3254 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决 ...

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 2025 年第二次临时股东会的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发 股份有限公司（以下简称"贵公司"）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）等中国现行有效的有关法律、行政法规、部门规章、规范性文件（以下 合称"法律法规"，仅为本法律意见书法律适用之目的，不包括中国香港特别 行政区、中国澳门特别行政区及台湾地区的法律法规）及《成都先导药物开发 股份有限公司章程》（以下简称《公司章程》）的有关规定，就贵公司 2025 年 第二次临时股东会（以下简称"本次股东会"）有关事宜出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序是否符合法律、行政法规 和《公司章程》的规定，以及出席本次股东会人员的资格、本次 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-053 成都先导药物开发股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 18 日 （星期二） 至 11 月 24 日 （星期 一）前登录上证路演中心网站首页点击"提问预征集"栏目或通过投 资者关系邮箱（investors@hitgen.com）进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年 第三季度经营成果、财务状况，公司计划于 2025 年 11 月 25 日(星期 二) 11:00-12:00 举行 2025 年第三季度业绩说明会，就投资者关心的 问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式 ...

Summary of Key Points Core Viewpoint - The announcement details the shareholding and reduction plan of Chengdu XianDao Pharmaceutical Development Co., Ltd., specifically regarding the share reduction by its shareholder Shenzhen JunTian Investment Enterprise (Limited Partnership) Group 1: Shareholding Information - Before the reduction plan, Shenzhen JunTian held 11,927,164 shares, accounting for 2.98% of the company's total share capital, with these shares being tradable since April 16, 2021 [1] Group 2: Reduction Plan Implementation - On August 5, 2025, the company disclosed a plan for Shenzhen JunTian to reduce its holdings by 2,000,000 shares, representing approximately 0.50% of the total share capital, to be executed within three months starting from August 8, 2025 [1] - By November 7, 2025, Shenzhen JunTian had reduced its holdings by 1,859,413 shares, which is 0.46% of the total share capital, leaving it with 10,067,751 shares, or 2.51% of the total [2] Group 3: Compliance and Results - The actual reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [4]

Core Points - Chengdu Xian Dao announced that shareholder Shenzhen Jun Tian Investment Enterprise (Limited Partnership) holds 11,927,164 shares, accounting for 2.98% of the total share capital [2] - During the reduction plan period, Shenzhen Jun Tian has cumulatively reduced its holdings by 1,859,413 shares through centralized bidding, representing 0.46% of the total share capital [2] - After the reduction, Shenzhen Jun Tian holds 10,067,751 shares, which is 2.51% of the total share capital [2]